<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Elan Corporation plc</title>
	<atom:link href="http://www.stockbloghub.com/tag/elan-corporation-plc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(IDCC) Money-Losing Companies That Beat the Market By 46% Each Year</title>
		<link>http://www.stockbloghub.com/2012/05/18/idcc-money-losing-companies-that-beat-the-market-by-46-each-year/100416</link>
		<comments>http://www.stockbloghub.com/2012/05/18/idcc-money-losing-companies-that-beat-the-market-by-46-each-year/100416#comments</comments>
		<pubDate>Fri, 18 May 2012 15:49:00 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Wireless Communications]]></category>
		<category><![CDATA[ADM]]></category>
		<category><![CDATA[Anadarko Petroleum Corporation]]></category>
		<category><![CDATA[APC]]></category>
		<category><![CDATA[Archer-Daniels-Midland Company]]></category>
		<category><![CDATA[CarMax Inc.]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[IDCC]]></category>
		<category><![CDATA[InterDigital Inc.]]></category>
		<category><![CDATA[KMX]]></category>
		<category><![CDATA[LEN]]></category>
		<category><![CDATA[Lennar Corporation]]></category>
		<category><![CDATA[Level 3 Communications Inc.]]></category>
		<category><![CDATA[LVLT]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[RIG]]></category>
		<category><![CDATA[Salesforce.com]]></category>
		<category><![CDATA[Spirit AeroSystems Holdings Inc]]></category>
		<category><![CDATA[SPR]]></category>
		<category><![CDATA[Transocean Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=100416</guid>
		<description><![CDATA[When I was young, stupid and chasing girls, good looks were the most important attribute a female could have as far as I was concerned. A disastrous relationship with an insane model changed my thinking pretty quickly. After splitting up with “Crazy Christine,” as my friends used to call her, I became much more interested in what was beneath the surface. The same can be said about my approach to stocks. Most investors look at earnings when evaluating a company. And that’s a great place to start. Typically, a company that’s consistently increasing its earnings has a healthy business, and the stock should emulate that success. But I like to dig deeper and really get to know the company. To do that, I look at cash flow. Cash flow is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/05/18/idcc-money-losing-companies-that-beat-the-market-by-46-each-year/100416/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Risk-Reward Balanced at Alkermes</title>
		<link>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426</link>
		<comments>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426#comments</comments>
		<pubDate>Wed, 07 Mar 2012 17:19:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94426</guid>
		<description><![CDATA[We are maintaining a Neutral rating on Alkermes (ALKS) with a target price of $18.00. Last month, Alkermes released its third quarter fiscal 2012 (ended December 31, 2011) financial results.  This was the first full quarter for Alkermes plc, formed in September 2011, following the merger of Waltham, Massachusetts based Alkermes, Inc. and Elan Drug Technologies (EDT), the drug delivery unit of  Elan Corporation (ELN). The merger has expanded the portfolio significantly resulting in a 185.7% increase in revenues during the quarter. The expanded portfolio caused management to increase the 2012 revenue projection. Revenues are projected in the range of $370-$400 million, up from the previous guidance of $350-$380 million. Given the expanded product portfolio, we expect the company to achieve/beat the increased guidance. Consequently, the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Gains &#8211; Earnings Miss Estimates</title>
		<link>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628</link>
		<comments>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628#comments</comments>
		<pubDate>Thu, 04 Aug 2011 15:47:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80628</guid>
		<description><![CDATA[Acorda Therapeutics Inc. (ACOR) recorded adjusted earnings of 7 cents per share for the second quarter of fiscal 2011, compared with a loss of 18 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 12 cents per share. Higher revenues during the quarter led to the surge in the company’s earnings. Revenues Quarterly revenues shot up 52.4% to $65.3 million, driven primarily by strong Ampyra sales. However, revenues marginally missed the Zacks Consensus Estimate of $67 million. Second quarter revenues comprised $62.9 million (up 55.3%) in product sales and $2.4 million (flat year over year) in license and royalty revenue. Sales of Ampyra, which was launched in March 2010, came in at $51.8 million, reflecting a year-over-year increase of 85%. Ampyra, aimed at improving walking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Presents Encouraging Data</title>
		<link>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229</link>
		<comments>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:31:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78229</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32).  ALKS 9070 is a once-monthly injectable extended release version of Bristol-Myer Squibb’s (BMY) schizophrenia drug Abilify (aripiprazole).  Alkermes intends to present complete data from the study at an upcoming medical conference. The double-blind, randomized, placebo-controlled 20-week study evaluated the safety, tolerability and pharmacokinetics of ALKS 9070 (once-monthly) at 3 doses in patients suffering from chronic, stable schizophrenia. Data from the study revealed that the candidate was generally well tolerated at all  doses and achieved therapeutically relevant plasma concentrations of Abilify. The pharmacokinetic profile backed the once-monthly dosing of ALKS 9070. Encouraged by the positive results, the company intends to commence a pivotal development program for the candidate by the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Evenly Poised</title>
		<link>http://www.stockbloghub.com/2011/06/24/alks-alkermes-evenly-poised/77334</link>
		<comments>http://www.stockbloghub.com/2011/06/24/alks-alkermes-evenly-poised/77334#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:32:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77334</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS) with a target price of $18.00. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. We are positive on Alkermes’ decision to buy  Elan Corporation’s (ELN) drug delivery unit. The deal is expected to boost Alkermes’ cash earnings immediately following its closure. The product portfolio at Alkermes will be strengthened following the merger. Alkermes currently has two marketed drugs namely Risperdal Consta and Vivitrol in its product portfolio. Risperdal Consta is marketed worldwide by Johnson &#38; Johnson (JNJ) for the treatment of schizophrenia and bipolar disorder. The drug is manufactured by Alkermes. The other approved product at Alkermes is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/alks-alkermes-evenly-poised/77334/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MS) Merck KGaA to Withdraw Multiple Sclerosis Drug</title>
		<link>http://www.stockbloghub.com/2011/06/23/ms-merck-kgaa-to-withdraw-multiple-sclerosis-drug/77278</link>
		<comments>http://www.stockbloghub.com/2011/06/23/ms-merck-kgaa-to-withdraw-multiple-sclerosis-drug/77278#comments</comments>
		<pubDate>Thu, 23 Jun 2011 20:03:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Investments]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77278</guid>
		<description><![CDATA[Merck KGaA (MKGAF) recently announced its plans to withdraw the regulatory applications filed with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), seeking approval to market cladribine as a treatment for relapsing-remitting multiple sclerosis (MS). This decision comes after Merck KGaA’s discussions with the FDA at the end-of-review meeting related to the new drug application (NDA) for cladribine. Merck KGaA believes that data from the ongoing clinical trials will not be sufficient to address the FDA’s requirements for approval. The company is of the view that to gain US and EU approval, it will have to conduct a new clinical trial program that would take several years to complete. Cladribine is currently marketed as Movectro in Australia and Russia for the treatment of relapsing-remitting MS. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/ms-merck-kgaa-to-withdraw-multiple-sclerosis-drug/77278/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec and Partner Elan Announce EU Label Update for Tysabri</title>
		<link>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127</link>
		<comments>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127#comments</comments>
		<pubDate>Wed, 22 Jun 2011 19:16:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77127</guid>
		<description><![CDATA[Recently, Biogen Idec, Inc. (BIIB) and partner Elan Corporation (ELN) announced that the European Commission (EC) has approved an update to the label for their multiple sclerosis (MS) drug Tysabri (natalizumab) in the European Union (EU). The updated label includes anti-JC Virus antibody status as an additional factor that could help stratify the risk of progressive multifocal leukoencephalopathy (PML) occurring in patients treated with Tysabri. The EC’s decision for the label update does not surprise us as in April 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) had backed the inclusion of the additional risk in the Tysabri label. The updated label in the EU will provide patients (treated with Tysabri) as well as doctors additional assistance in identifying the risk of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/biib-biogen-idec-and-partner-elan-announce-eu-label-update-for-tysabri/77127/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Gets Mixed Data on Ampyra</title>
		<link>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214</link>
		<comments>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214#comments</comments>
		<pubDate>Thu, 16 Jun 2011 14:45:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76214</guid>
		<description><![CDATA[Acorda Therapeutics, Inc. (ACOR) recently reported an analysis of data on Ampyra (dalfampridine) at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. The analysis demonstrated improvements in walking ability of patients on Ampyra as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12). The analysis comprised data from a phase II trial and two phase III trials of Ampyra. These data were a part of Acorda’s new drug application (NDA) submission to the US Food and Drug Administration (FDA) for the approval of the drug. At the CMSC meeting, another set of study data on Ampyra called – UTI (urinary tract infection) Incidence among MS Patients Treated with Dalfampridine 10 mg Twice Daily – was also presented. As the name suggests, the study evaluated the incidence ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/acor-acorda-therapeutics-gets-mixed-data-on-ampyra/76214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BJ) Company News for June 10, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/14/bj-company-news-for-june-10-2011-corporate-summary-2/76077</link>
		<comments>http://www.stockbloghub.com/2011/06/14/bj-company-news-for-june-10-2011-corporate-summary-2/76077#comments</comments>
		<pubDate>Tue, 14 Jun 2011 15:07:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Discount Variety Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[BJ]]></category>
		<category><![CDATA[BJ's Wholesale Club Inc.]]></category>
		<category><![CDATA[Concho Resources Inc]]></category>
		<category><![CDATA[CXO]]></category>
		<category><![CDATA[DIS]]></category>
		<category><![CDATA[EEE]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Evergreen Energy Inc]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[HLS Systems International Limited]]></category>
		<category><![CDATA[HOLI]]></category>
		<category><![CDATA[M]]></category>
		<category><![CDATA[Macy's Inc.]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[Nasdaq OMX Group Inc]]></category>
		<category><![CDATA[NDAQ]]></category>
		<category><![CDATA[SJM]]></category>
		<category><![CDATA[The J. M. Smucker Company]]></category>
		<category><![CDATA[Titan Machinery Inc.]]></category>
		<category><![CDATA[TITN]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[Walt Disney Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76077</guid>
		<description><![CDATA[•    On Thursday, 3M Company (NYSE:MMM) said it has concluded an agreement to buy manufacturer of quick cure, aircraft sealants Advanced Chemistry &#38; Technology. The acquisition will enhance and expand 3M&#8217;s product availability in the aerospace market •    Evergreen Energy Inc. (NYSE:EEE) said it has completed the formation of its venture with Australian listed mineral resources company WPG Resources. K-Fuel is Evergreen&#8217;s coal upgrading technology •    Titan Machinery Inc. (NASDAQ:TITN) reported Q1 EPS of $0.40, ahead of the Zacks Consensus Estimate of $0.23 per share. Revenues grew 54.9% year-over-year to $318.2 million, easily surpassing the Zacks Consensus Estimate of $245.0 million •    The J. M. Smucker Company (NYSE:SJM) reported Q4 EPS of $1.00 ex-items, marginally above the Zacks Consensus Estimate of $0.98 per share. Revenue for the quarter grew 11% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/bj-company-news-for-june-10-2011-corporate-summary-2/76077/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BJ) Company News for June 10, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/10/bj-company-news-for-june-10-2011-corporate-summary/75980</link>
		<comments>http://www.stockbloghub.com/2011/06/10/bj-company-news-for-june-10-2011-corporate-summary/75980#comments</comments>
		<pubDate>Fri, 10 Jun 2011 15:55:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Discount Variety Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[BJ]]></category>
		<category><![CDATA[BJ's Wholesale Club Inc.]]></category>
		<category><![CDATA[Concho Resources Inc]]></category>
		<category><![CDATA[CXO]]></category>
		<category><![CDATA[DIS]]></category>
		<category><![CDATA[EEE]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Evergreen Energy Inc]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[HLS Systems International Limited]]></category>
		<category><![CDATA[HOLI]]></category>
		<category><![CDATA[M]]></category>
		<category><![CDATA[Macy's Inc.]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[Nasdaq OMX Group Inc]]></category>
		<category><![CDATA[NDAQ]]></category>
		<category><![CDATA[SJM]]></category>
		<category><![CDATA[The J. M. Smucker Company]]></category>
		<category><![CDATA[Titan Machinery Inc.]]></category>
		<category><![CDATA[TITN]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[Walt Disney Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75980</guid>
		<description><![CDATA[•    On Thursday, 3M Company (NYSE:MMM) said it has concluded an agreement to buy manufacturer of quick cure, aircraft sealants Advanced Chemistry &#38; Technology. The acquisition will enhance and expand 3M&#8217;s product availability in the aerospace market •    Evergreen Energy Inc. (NYSE:EEE) said it has completed the formation of its venture with Australian listed mineral resources company WPG Resources. K-Fuel is Evergreen&#8217;s coal upgrading technology •    Titan Machinery Inc. (NASDAQ:TITN) reported Q1 EPS of $0.40, ahead of the Zacks Consensus Estimate of $0.23 per share. Revenues grew 54.9% year-over-year to $318.2 million, easily surpassing the Zacks Consensus Estimate of $245.0 million •    The J. M. Smucker Company (NYSE:SJM) reported Q4 EPS of $1.00 ex-items, marginally above the Zacks Consensus Estimate of $0.98 per share. Revenue for the quarter grew 11% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/10/bj-company-news-for-june-10-2011-corporate-summary/75980/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Stock Market News for May 10, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/05/10/alks-stock-market-news-for-may-10-2011-market-news/73711</link>
		<comments>http://www.stockbloghub.com/2011/05/10/alks-stock-market-news-for-may-10-2011-market-news/73711#comments</comments>
		<pubDate>Tue, 10 May 2011 16:55:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[Baker Hughes Inc.]]></category>
		<category><![CDATA[BHI]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Dollar Thrifty Automotive Group Inc]]></category>
		<category><![CDATA[DTG]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[Frontier Oil Corporation]]></category>
		<category><![CDATA[FTO]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hertz Global Holdings Inc.]]></category>
		<category><![CDATA[HOC]]></category>
		<category><![CDATA[Holly Corporation]]></category>
		<category><![CDATA[HTZ]]></category>
		<category><![CDATA[Marathon Oil Corporation]]></category>
		<category><![CDATA[MRO]]></category>
		<category><![CDATA[NVDA]]></category>
		<category><![CDATA[NVIDIA Corporation]]></category>
		<category><![CDATA[SGY]]></category>
		<category><![CDATA[Stone Energy Corporation]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73711</guid>
		<description><![CDATA[After suffering a slump last week, commodities made a strong comeback yesterday and lifted the benchmarks higher. Energy shares joined in on the uptrend as crude prices once again rose above $100 per barrel. Meanwhile fresh worries about Greece’s credit ratings partially limited gains. The Dow Jones Industrial Average (DJIA) rose 0.4% to close at 12,684.68. The Standard &#38; Poor 500 (S&#38;P 500) gained 0.5% and finished the day at 1,346.29. The Nasdaq Composite Index increased 0.6% to settle at 2,843.25. The fear-gauge CBOE Volatility Index dropped down to almost 17. On the New York Stock Exchange, composite volumes were low, at only 3 billion shares. For every couple of stocks that gained, one stock moved down. Markets witnessed a massive sell off of commodities last week as investors chose ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/10/alks-stock-market-news-for-may-10-2011-market-news/73711/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermesto Buy Elan Unit for $960 Million</title>
		<link>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637</link>
		<comments>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637#comments</comments>
		<pubDate>Mon, 09 May 2011 22:55:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[HBC]]></category>
		<category><![CDATA[HSBC HLDGS PLC ADS]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73637</guid>
		<description><![CDATA[Recently, Alkermes, Inc. (ALKS) inked a deal with Elan Corporation (ELN) to buy the latter’s Elan Drug Technologies (EDT) segment. The EDT segment is the drug delivery unit of Elan. The merger, expected to close in the third quarter of calendar 2011, is worth approximately $960 million. The merged entity will be known as Alkermes plc and will be headquartered in Dublin, Ireland. The deal, expected to boost Alkermes’ cash earnings immediately following its closure, has been cleared by the board of directors of both companies. Morgan Stanley &#38; Co. (MS) and HSBC (HBC) have agreed to finance up to $450 million of the deal through term loans to Alkermes. Per the terms of the deal, Alkermes will make a cash payment of $500 million apart from giving Elan 31.9 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Reports Loss That Missed Expectations</title>
		<link>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532</link>
		<comments>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532#comments</comments>
		<pubDate>Sun, 08 May 2011 15:50:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73532</guid>
		<description><![CDATA[Acorda Therapeutics Inc. (ACOR) posted a loss of 2 cents per share for the first quarter of fiscal 2011, compared with a loss of 56 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 18 cents per share. Despite increased revenues, higher operating expenses resulted in a loss during the quarter. Quarterly Details Quarterly revenues saw a whopping 245.3% increase to reach $61.3 million, with Ampyra sales exceeding expectations. However, revenues missed the Zacks Consensus Estimate of $65 million. Fourth quarter revenues comprised $58.9 million (up 282.9%) in product sales and $2.4 million (flat year over year) in license and royalty revenue. Sales of Ampyra, which was launched in March 2010, came in at $46.8 million. Ampyra, aimed at improving walking speed in multiple sclerosis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/acor-acorda-therapeutics-reports-loss-that-missed-expectations/73532/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Earnings Above Estimates on Multiple Sclerosis Drugs</title>
		<link>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234</link>
		<comments>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234#comments</comments>
		<pubDate>Tue, 26 Apr 2011 15:42:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72234</guid>
		<description><![CDATA[Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based compensation expense, first quarter 2011 earnings came in at $1.43 per share. Performance was boosted by higher multiple sclerosis (MS) drug revenues, lower costs and lower share count. Biogen has been looking to streamline its operations and increase efficiencies through the implementation of a restructuring program. The company’s restructuring program includes initiatives like streamlining of operations, shutting down of facilities, and workforce reduction. Biogen is also focusing its development efforts on neurology and biologics. First quarter revenues increased 9% to $1.20 billion, with MS drugs, Tysabri and Avonex being the primary growth drivers. Revenues were above the Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Earnings Report Beats The Street</title>
		<link>http://www.stockbloghub.com/2011/04/23/biib-biogen-idec-earnings-report-beats-the-street/72122</link>
		<comments>http://www.stockbloghub.com/2011/04/23/biib-biogen-idec-earnings-report-beats-the-street/72122#comments</comments>
		<pubDate>Sat, 23 Apr 2011 15:25:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72122</guid>
		<description><![CDATA[Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based compensation expense, first quarter 2011 earnings came in at $1.43 per share. Performance was boosted by higher mutliple sclerosis (MS) drug revenues, lower costs and lower share count. Biogen has been looking to streamline its operations and increase efficiencies through the implementation of a restructuring program. The company’s restructuring program includes initiatives like streamlining of operations, shutting down of facilities, and workforce reduction. Biogen is also focusing its development efforts on neurology and biologics. First quarter revenues increased 9% to $1.20 billion, with MS drugs, Tysabri and Avonex being the primary growth drivers. Revenues were above the Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/23/biib-biogen-idec-earnings-report-beats-the-street/72122/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PDLI) PDL BioPharma Ramps Up Earnings &#8211; Settles Disputes</title>
		<link>http://www.stockbloghub.com/2011/03/07/pdli-pdl-biopharma-ramps-up-earnings-settles-disputes/67805</link>
		<comments>http://www.stockbloghub.com/2011/03/07/pdli-pdl-biopharma-ramps-up-earnings-settles-disputes/67805#comments</comments>
		<pubDate>Mon, 07 Mar 2011 18:02:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67805</guid>
		<description><![CDATA[PDL BioPharma Inc. (PDLI) posted fourth quarter earnings of 20 cents per share, above the year-ago figure of 17 cents. Higher revenues boosted earnings in the quarter. Earnings per share were, however, a penny short of the Zacks Consensus Estimate of 21 cents. For full year 2010, PDL reported earnings per share of 97 cents, down from $1.06 per share in 2009 but ahead of the Zacks Consensus Estimate of 90 cents. Full year 2010 revenues of $345 million were well above the prior-year figure of $318.2 million. Revenues also beat the Zacks Consensus Estimate of $343 million. 2009 revenues included royalties from MedImmune, a subsidiary of AstraZeneca (AZN), on sales of Synagis, which PDL no longer receives. Excluding this revenue, sales were up 30% over the prior year. Quarterly ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/07/pdli-pdl-biopharma-ramps-up-earnings-settles-disputes/67805/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Quarterly Earnings Report Beats by a Wide Margin</title>
		<link>http://www.stockbloghub.com/2011/02/01/biib-biogen-quarterly-earnings-report-beats-by-a-wide-margin/66175</link>
		<comments>http://www.stockbloghub.com/2011/02/01/biib-biogen-quarterly-earnings-report-beats-by-a-wide-margin/66175#comments</comments>
		<pubDate>Wed, 02 Feb 2011 05:06:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66175</guid>
		<description><![CDATA[Biogen Idec (BIIB) reported fourth-quarter earnings per share of $1.41, well above the Zacks Consensus Estimate of $1.23 and the year-earlier figure of $1.18. Excluding the impact of stock-based compensation expense, fourth quarter 2010 earnings came in at $1.42 per share. Full year earnings came in at $5.03 per share, beating the Zacks Consensus Estimate of $4.89 and the year-ago earnings of $4.03. Excluding the impact of stock-based compensation expense, 2010 earnings came in at $5.15 per share. Performance was boosted by higher revenues and lower share count. Fourth quarter revenues increased 8.2% to $1.22 billion, with Tysabri and Avonex being the primary growth drivers. Revenues were above the Zacks Consensus Estimate of $1.17 billion. Full year revenues increased 7.7% to $4.72 billion, above the Zacks Consensus Estimate of $4.67 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/01/biib-biogen-quarterly-earnings-report-beats-by-a-wide-margin/66175/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PDLI) PDL BioPharma Meets Earnings Forecast &#8211; Beats Revenue Forecast</title>
		<link>http://www.stockbloghub.com/2010/11/17/pdli-pdl-biopharma-meets-earnings-forecast-beats-revenue-forecast/59524</link>
		<comments>http://www.stockbloghub.com/2010/11/17/pdli-pdl-biopharma-meets-earnings-forecast-beats-revenue-forecast/59524#comments</comments>
		<pubDate>Thu, 18 Nov 2010 05:07:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59524</guid>
		<description><![CDATA[PDL BioPharma Inc. (PDLI) posted third quarter earnings of 25 cents per share, in line with the Zacks Consensus Estimate, but below the year-ago figure of 29 cents. Earnings declined in the quarter, despite the increase in revenue, due to higher selling and general expenses. Quarterly Details Third quarter revenue of $86.4 million was higher than the Zacks Consensus Estimate of $84 million and about 21% above the year-ago revenue. The top-line increase resulted from higher 2Q10 sales of Roche’s (RHHBY) Avastin, Herceptin, and Lucentis, and Biogen/Elan’s (BIIB/ELN) Tysabri, on which PDL BioPharma received royalties in 3Q10. Revenue was, however, in line with the company’s guidance of $86 million provided in September 2010. Quarterly general and administrative expenses increased from $5.3 million in the year-earlier quarter to $11.1 million in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/17/pdli-pdl-biopharma-meets-earnings-forecast-beats-revenue-forecast/59524/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ELN) Elan Quarterly Report Matches Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/11/03/eln-elan-quarterly-report-matches-earnings-estimates/57476</link>
		<comments>http://www.stockbloghub.com/2010/11/03/eln-elan-quarterly-report-matches-earnings-estimates/57476#comments</comments>
		<pubDate>Wed, 03 Nov 2010 15:12:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=57476</guid>
		<description><![CDATA[Elan Corporation plc (ELN) reported loss per share of 7 cents for the third quarter of 2010, in line with the Zacks Consensus Estimate but way below the year-ago earnings of 11 cents per share. The year-ago quarter saw Elan recording a divestment gain of $107.7 million, which is primarily the reason for the substantial year-over-year decline in earnings. On an adjusted basis, the company reported a loss of 5 cents per share, an improvement from a loss of 11 cents per share in the third quarter of 2009. Revenues Quarterly revenues declined 2% year over year to $281.4 million and also missed the Zacks Consensus Estimate of $298 million. Elan operates through two segments – BioNeurology and Elan Drug Technologies (EDT). Revenues from the BioNeurology segment went up 0.2% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/03/eln-elan-quarterly-report-matches-earnings-estimates/57476/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Beats Earnings Forecast by a Wide Margin</title>
		<link>http://www.stockbloghub.com/2010/10/26/biib-biogen-beats-earnings-forecast-by-a-wide-margin/56648</link>
		<comments>http://www.stockbloghub.com/2010/10/26/biib-biogen-beats-earnings-forecast-by-a-wide-margin/56648#comments</comments>
		<pubDate>Tue, 26 Oct 2010 15:55:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56648</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) reported third-quarter earnings per share of $1.33, well above the Zacks Consensus Estimate of $1.20 and the year-earlier figure of $1.09. Excluding the impact of stock-based compensation expense, third quarter 2010 earnings came in at $1.35 per share. Performance was boosted by higher revenues and lower share count. Revenues increased 5% to $1.18 billion, with Tysabri and Rituxan being the primary growth drivers. Revenues were slightly above the Zacks Consensus Estimate of $1.16 billion. Revenue by Major Products Third quarter Tysabri revenues came in at $221 million, up 7% from the prior period. Global in-market net sales of Tysabri, which is partnered with Elan Corp. (ELN), came in at $307 million (up 9%) in the third quarter of 2010. Tysabri global sales consisted of US sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/26/biib-biogen-beats-earnings-forecast-by-a-wide-margin/56648/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Delivered Earnings Surprises Over the Past Few Quarters</title>
		<link>http://www.stockbloghub.com/2010/10/25/biib-biogen-idec-delivered-earnings-surprises-over-the-past-few-quarters/56422</link>
		<comments>http://www.stockbloghub.com/2010/10/25/biib-biogen-idec-delivered-earnings-surprises-over-the-past-few-quarters/56422#comments</comments>
		<pubDate>Tue, 26 Oct 2010 04:43:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56422</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) is slated to announce its third quarter results on October 26. The Zacks Consensus Estimate is $1.20, well above the year-earlier earnings of $1.09. Second Quarter Highlights Biogen Idec Inc. reported second-quarter earnings per share of $1.27, well above the Zacks Consensus Estimate of $1.08 and the year-earlier figure of $0.73. Performance was boosted by higher revenues. Revenues increased 11% to $1.2 billion, with Tysabri and Rituxan being the primary growth drivers. Second quarter Tysabri revenues came in at $219 million, up 17% from the prior period. Global in-market net sales of Tysabri, which is partnered with Elan Corp. (ELN), came in at $298 million (up 17%) in the second quarter of 2010. Despite carrying a black-box warning for the risk of progressive multifocal leukoencephalopathy (PML) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/25/biib-biogen-idec-delivered-earnings-surprises-over-the-past-few-quarters/56422/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PDLI) PDL BioPharma Announces Third-Quarter Outlook</title>
		<link>http://www.stockbloghub.com/2010/09/07/pdli-pdl-biopharma-announces-third-quarter-outlook/50221</link>
		<comments>http://www.stockbloghub.com/2010/09/07/pdli-pdl-biopharma-announces-third-quarter-outlook/50221#comments</comments>
		<pubDate>Tue, 07 Sep 2010 13:48:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50221</guid>
		<description><![CDATA[PDL BioPharma Inc. (PDLI) recently announced that it expects to generate third-quarter 2010 (ending September 30) revenue of $86.0 million, representing an increase of 20% over the year-ago revenue of $71.4 million. The increase is primarily attributable to higher sales of Avastin, Herceptin, Lucentis and Tysabri during the second quarter, on which PDL BioPharma will receive royalties in the third quarter. The Zacks Consensus Estimate for the third quarter is $3 million below the company&#8217;s revenue guidance. The third quarter revenue outlook is inclusive of the $2.9 million earned by the company on Eurodollar foreign currency hedging contracts, initiated in January 2010. PDL BioPharma derives royalty revenue from the worldwide net sales of humanized antibody products, which include Roche Holdings Ltd.&#8217;s (RHHBY) Avastin, Herceptin, Xolair, and Lucentis Elan Corporation plc&#8216;s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/07/pdli-pdl-biopharma-announces-third-quarter-outlook/50221/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Second Quarter 2010 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/07/19/biib-biogen-idec-second-quarter-2010-earnings-preview/44017</link>
		<comments>http://www.stockbloghub.com/2010/07/19/biib-biogen-idec-second-quarter-2010-earnings-preview/44017#comments</comments>
		<pubDate>Mon, 19 Jul 2010 22:04:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44017</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) is set to announce its second quarter 2010 results on Tuesday, July 20, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter is $1.08 per share (with a downside of 0.93%), compared to the 73 cents per share earned in the year-earlier period. First Quarter Recap Biogen’s first-quarter earnings per share of $1.04 was a cent above the year-ago figure of $1.03. Excluding the impact of stock-based compensation expense, earnings came in at $1.08 per share. The Zacks Consensus Estimate for the quarter was $1.12. Despite an increase in revenue, performance was impacted by higher expenses including a $13 million charge taken due to the recently passed health care reform. Revenue increased 7% to $1.1 billion, with Tysabri and Avonex being the primary ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/19/biib-biogen-idec-second-quarter-2010-earnings-preview/44017/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation Quarterly Report Shows Wider Loss</title>
		<link>http://www.stockbloghub.com/2010/05/17/mdvn-medivation-quarterly-report-shows-wider-loss/37433</link>
		<comments>http://www.stockbloghub.com/2010/05/17/mdvn-medivation-quarterly-report-shows-wider-loss/37433#comments</comments>
		<pubDate>Mon, 17 May 2010 22:09:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37433</guid>
		<description><![CDATA[Medivation Inc. (MDVN) reported a loss of 51 cents per share in the first quarter of 2010, exceeding the Zacks Consensus Estimate of a loss of 42 cents and the year-ago loss of 19 cents. Lower revenues and higher expenses led to the higher loss. Revenues for the quarter were $15.7 million, consisting of partial recognition of the non-refundable upfront payment of $225 million received from Pfizer (PFE) in October 2008 and $110 million received from Astellas in late 2009. The upfront payments are being recognized on a straight-line basis – while the Pfizer payment will be recognized through the second quarter of 2013, the Astellas payment will be recognized through the fourth quarter of 2014. Revenues were $16.3 million in the year-ago period. Operating expenses grew from $22.1 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/17/mdvn-medivation-quarterly-report-shows-wider-loss/37433/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec&#8217;s Earnings Report Misses Consensus</title>
		<link>http://www.stockbloghub.com/2010/04/21/biib-biogen-idecs-earnings-report-misses-consensus/34440</link>
		<comments>http://www.stockbloghub.com/2010/04/21/biib-biogen-idecs-earnings-report-misses-consensus/34440#comments</comments>
		<pubDate>Wed, 21 Apr 2010 16:23:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34440</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) reported first-quarter earnings per share of $1.04, a cent above the year-ago figure of $1.03 but well below the Zacks Consensus Estimate of $1.12. Excluding the impact of stock-based compensation expense, earnings came in at $1.08 per share. Despite an increase in revenue, performance was impacted by higher expenses including a $13 million charge taken due to the recent health care reform. Revenue increased 7% to $1.1 billion, with Tysabri and Avonex being the primary growth drivers. Revenue by Major Products First quarter Tysabri revenues came in at $219 million, up 32% from the prior period. Global in-market net sales of Tysabri, which is partnered with Elan Corp. (ELN), came in at $292 million (up 28%) in the first quarter of 2010. Tysabri global sales consisted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/21/biib-biogen-idecs-earnings-report-misses-consensus/34440/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation Announces Workforce Reductions</title>
		<link>http://www.stockbloghub.com/2010/04/01/mdvn-medivation-announces-workforce-reductions/32520</link>
		<comments>http://www.stockbloghub.com/2010/04/01/mdvn-medivation-announces-workforce-reductions/32520#comments</comments>
		<pubDate>Thu, 01 Apr 2010 14:59:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32520</guid>
		<description><![CDATA[Medivation, Inc. (MDVN) recently announced that it intends to reduce its workforce by 20% or 23 people to save costs and focus its resources towards research and development activities related to dimebon and MDV3100. Medivation also announced the departure of its senior vice president of clinical development and the vice president of commercial development. The company said that it is no longer looking for a new Chief Financial Officer (CFO) as this post will be filled by the current Chief Business Officer (CBO). Medivation’s workforce reduction announcement comes on the heels of disappointing phase III results reported earlier this month on its lead pipeline candidate, dimebon. Dimebon, which is being developed for Alzheimer’s disease in collaboration with Pfizer, Inc. (PFE), failed to achieve both its primary and secondary endpoints in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/mdvn-medivation-announces-workforce-reductions/32520/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec&#8217;s Tysabri Against Teva&#8217;s Copaxone and Merck Serono/Pfizer’s Rebif</title>
		<link>http://www.stockbloghub.com/2010/03/27/biib-biogen-idecs-tysabri-against-tevas-copaxone-and-merck-seronopfizer%e2%80%99s-rebif/32022</link>
		<comments>http://www.stockbloghub.com/2010/03/27/biib-biogen-idecs-tysabri-against-tevas-copaxone-and-merck-seronopfizer%e2%80%99s-rebif/32022#comments</comments>
		<pubDate>Sat, 27 Mar 2010 20:19:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32022</guid>
		<description><![CDATA[Biogen Idec (BIIB) and Elan Corporation, plc (ELN) recently announced that they have started enrolling patients for a phase IIIb head-to-head study between Tysabri and Teva Pharmaceuticals’ (TEVA) Copaxone and Merck Serono/Pfizer’s (PFE) Rebif. The randomized, rater-blinded, active-controlled study (SURPASS) will evaluate the efficacy of Biogen/Elan’s Tysabri in patients with relapsing remitting multiple sclerosis (RRMS) who switch to the drug from other treatments like Copaxone or Rebif. With a considerable number of MS patients relapsing or showing signs of disease progression despite being treated with therapies like Copaxone and Rebif, the trial will study whether the early use of Tysabri could result in better outcomes compared to staying on current therapy or switching between Copaxone and Rebif. The study, which will be conducted with 1,800 patients across 27 countries, will ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/27/biib-biogen-idecs-tysabri-against-tevas-copaxone-and-merck-seronopfizer%e2%80%99s-rebif/32022/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation Reports Wider Fourth Quarter Loss</title>
		<link>http://www.stockbloghub.com/2010/03/16/mdvn-medivation-reports-wider-fourth-quarter-loss/30766</link>
		<comments>http://www.stockbloghub.com/2010/03/16/mdvn-medivation-reports-wider-fourth-quarter-loss/30766#comments</comments>
		<pubDate>Tue, 16 Mar 2010 22:50:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30766</guid>
		<description><![CDATA[Medivation Inc. (MDVN) reported dismal results in the fourth quarter of 2009 with net loss coming in at 78 cents per share, wider than the Zacks Consensus Estimate of a net loss of 57 cents and the year-ago net loss of 26 cents. Despite full year revenues increasing to $69.3 million, net loss increased due to higher operating expenses. Net loss for 2009 came in at $1.71, wider than the Zacks Consensus Estimate of a net loss of $1.42. Full year revenues consisted of partial recognition of the non-refundable upfront payment of $225 million received from Pfizer (PFE) in Oct 2008 and $110 million received from Astellas in the fourth quarter of 2009. While the upfront payment from Pfizer is being recognized on a straight-line basis through the first quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/16/mdvn-medivation-reports-wider-fourth-quarter-loss/30766/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation Shares Fall on Alzheimer&#8217;s Phase III Data</title>
		<link>http://www.stockbloghub.com/2010/03/04/mdvn-medivation-shares-fall-on-alzheimers-phase-iii-data/29721</link>
		<comments>http://www.stockbloghub.com/2010/03/04/mdvn-medivation-shares-fall-on-alzheimers-phase-iii-data/29721#comments</comments>
		<pubDate>Thu, 04 Mar 2010 16:33:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29721</guid>
		<description><![CDATA[Medivation, Inc. (MDVN) shares fell 67% following the release of disappointing phase III results on lead pipeline candidate dimebon. The company, along with partner Pfizer, Inc. (PFE), suffered a huge setback when dimebon failed to achieve both its primary and secondary endpoints in the CONNECTION study. The phase III, multi-national, double-blind, placebo-controlled safety and efficacy trial was conducted across 63 sites in North America, Europe, and South America with 598 patients suffering from mild-to-moderate Alzheimer’s disease. Results showed that dimebon failed to achieve a statistically significant improvement over placebo. These results are extremely disappointing for both Medivation and Pfizer. Pfizer has already invested a significant amount of money towards the development of the candidate. The company made an upfront payment of $225 million to Medivation under the collaboration agreement and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/04/mdvn-medivation-shares-fall-on-alzheimers-phase-iii-data/29721/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Beats Expectations and Guides Higher</title>
		<link>http://www.stockbloghub.com/2010/02/10/biib-biogen-idec-beats-expectations-and-guides-higher/27581</link>
		<comments>http://www.stockbloghub.com/2010/02/10/biib-biogen-idec-beats-expectations-and-guides-higher/27581#comments</comments>
		<pubDate>Wed, 10 Feb 2010 21:07:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27581</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) reported fourth quarter earnings per share of $1.18, beating the Zacks Consensus Estimate of $1.05. The company reported earnings of 91 cents in the year-ago period. Performance was driven by higher revenues and lower expenses. Revenues increased 5% to $1.1 billion, with Tysabri and Avonex being the primary growth drivers. For the full year, the company reported earnings of $4.03, well above the Zacks Consensus Estimate of $3.93 and the year-ago earnings of $3.58. Full-year revenues increased 7% to $4.4 billion. Revenue by Major Products Fourth quarter Tysabri revenues came in at $216 million, up 39% from the prior period. Global in-market net sales of Tysabri, which is partnered with Elan Corp. (ELN), came in at $296 million (up 37%) in the fourth quarter of 2009. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/10/biib-biogen-idec-beats-expectations-and-guides-higher/27581/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen&#8217;s Tysabri European Medicines Agency Review Finished</title>
		<link>http://www.stockbloghub.com/2010/01/27/biib-biogens-tysabri-european-medicines-agency-review-finished/26117</link>
		<comments>http://www.stockbloghub.com/2010/01/27/biib-biogens-tysabri-european-medicines-agency-review-finished/26117#comments</comments>
		<pubDate>Wed, 27 Jan 2010 18:29:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26117</guid>
		<description><![CDATA[Last week, the European Medicines Agency (EMEA) finalized a review of Biogen Idec’s (BIIB) Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML) associated with the prolonged use of the drug. PML is a rare brain infection caused by the JC virus. The agency’s Committee for Medicinal Products for Human Use (CHMP) arrived at the conclusion that the risk of a patient developing PML increases after having taken the drug for two years or more, though the risk remains low. However, the benefits of the drug outweigh its risks. Given the importance of the early detection of PML, the committee has recommended certain measures to ensure that patients and doctors are aware of the associated risks. Measures include updating product information to include the high risk of developing PML ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/27/biib-biogens-tysabri-european-medicines-agency-review-finished/26117/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics&#8217; Multiple Sclerosis Drug Gets FDA Clearance</title>
		<link>http://www.stockbloghub.com/2010/01/25/acor-acorda-therapeutics-multiple-sclerosis-drug-gets-fda-clearance/25972</link>
		<comments>http://www.stockbloghub.com/2010/01/25/acor-acorda-therapeutics-multiple-sclerosis-drug-gets-fda-clearance/25972#comments</comments>
		<pubDate>Tue, 26 Jan 2010 04:36:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25972</guid>
		<description><![CDATA[Recently, Acorda Therapeutics Inc. (ACOR) announced that the U.S. Food and Drug Administration (FDA) has cleared its oral drug Ampyra (dalfampridine) which aims to improve walking speed in patients suffering from multiple sclerosis (MS). The company expects to launch the drug in the United States in March 2010. Ampyra is the first drug to get FDA approval for treating walking impairment in MS patients. Ampyra, previously known as Fampridine-SR, is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP), which was previously referred to as fampridine. The drug enjoys orphan drug designation from the U.S. agency, thereby providing it with seven years of market exclusivity. Ampyra will be manufactured under a license and supply agreement with Elan Pharma International Limited, a subsidiary of Elan Corporation, plc (ELN). However, Ampyra will ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/25/acor-acorda-therapeutics-multiple-sclerosis-drug-gets-fda-clearance/25972/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen&#8217;s Tysabri is a Blockbuster!</title>
		<link>http://www.stockbloghub.com/2010/01/13/biib-biogens-tysabri-is-a-blockbuster/24853</link>
		<comments>http://www.stockbloghub.com/2010/01/13/biib-biogens-tysabri-is-a-blockbuster/24853#comments</comments>
		<pubDate>Wed, 13 Jan 2010 17:40:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24853</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) recently announced that its multiple sclerosis (MS) drug Tysabri achieved blockbuster status in 2009. Sales of the drug, which is approved for relapsing forms of MS in the US and for relapsing-remitting MS in the EU, achieved $1 billion in sales in 2009. Tysabri is marketed by Biogen in collaboration with Elan Corp. (ELN). In addition to reporting Tysabri sales, Biogen provided an update on other products and pipeline candidates. The company stated that it intends to grow Avonex and Rituxan sales through lifecycle management. Meanwhile, Biogen recently submitted a marketing authorization application seeking approval from the European Medicines Agency for Fampridine prolonged release tablets. The company is seeking approval for the use of the candidate to improve the walking ability of adult patients with MS. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/13/biib-biogens-tysabri-is-a-blockbuster/24853/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Announces New PML Cases In Patients Taking Their Multiple Sclerosis Drug Tysabri</title>
		<link>http://www.stockbloghub.com/2010/01/07/biib-biogen-idec-announces-new-pml-cases-in-patients-taking-their-multiple-sclerosis-drug-tysabri/24413</link>
		<comments>http://www.stockbloghub.com/2010/01/07/biib-biogen-idec-announces-new-pml-cases-in-patients-taking-their-multiple-sclerosis-drug-tysabri/24413#comments</comments>
		<pubDate>Thu, 07 Jan 2010 17:42:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24413</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) recently announced that 4 more cases of progressive multifocal leukeoencephalopathy (PML), a potentially deadly brain infection, were observed in November in patients taking its multiple sclerosis drug Tysabri. This brings the total number of PML cases to 28. The company will be providing information on additional cases of PML observed in the month of December shortly. Tysabri is the second multiple sclerosis product in Biogen’s portfolio and is a major growth driver for the company. Biogen was withdrawn from US markets in 2005 due to the PML concern but was reintroduced after one year with a strict warning regarding the occurrence of PML. When re-approved in June 2006, Biogen and partner Elan (ELN), the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/07/biib-biogen-idec-announces-new-pml-cases-in-patients-taking-their-multiple-sclerosis-drug-tysabri/24413/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson Aquires a Privately-Held Medical Devices Company</title>
		<link>http://www.stockbloghub.com/2009/12/17/jnj-johnson-johnson-aquires-a-privately-held-medical-devices-company/23159</link>
		<comments>http://www.stockbloghub.com/2009/12/17/jnj-johnson-johnson-aquires-a-privately-held-medical-devices-company/23159#comments</comments>
		<pubDate>Fri, 18 Dec 2009 01:04:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23159</guid>
		<description><![CDATA[Johnson &#38; Johnson&#8217;s (JNJ) surgical care company Ethicon decided to acquire a privately-held medical devices company, Acclarent, for approximately $785 million. The transaction, expected to close in the first quarter of 2010, is likely to have a dilutive impact of approximately 3– 4 cents on Johnson &#38; Johnson&#8217;s 2010 adjusted earnings per share. Acclarent develops devices to treat abnormalities associated with ear, nose and throat (ENT) with specialization in products used for sinus surgery. We believe there is huge potential for Acclarent’s business, as its balloon sinuplasty technology and other related products offer ENT patients a better alternative compared to currently available treatment options including conventional surgical approaches. Johnson &#38; Johnson has been in an acquisitive mode during the year, the Acclarent buyout being the latest. Earlier this year, in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/17/jnj-johnson-johnson-aquires-a-privately-held-medical-devices-company/23159/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) GlaxoSmithKline Earns FDA Approval for Arzerra, a Chronic Lymphocytic Leukemia Drug</title>
		<link>http://www.stockbloghub.com/2009/10/28/gsk-glaxosmithkline-earns-fda-approval-for-arzerra-a-chronic-lymphocytic-leukemia-drug/19135</link>
		<comments>http://www.stockbloghub.com/2009/10/28/gsk-glaxosmithkline-earns-fda-approval-for-arzerra-a-chronic-lymphocytic-leukemia-drug/19135#comments</comments>
		<pubDate>Thu, 29 Oct 2009 04:34:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19135</guid>
		<description><![CDATA[GlaxoSmithKline (GSK) and Denmark-based Genmab received some good news with the US Food and Drug Administration’s (FDA) approval for Arzerra (ofatumumab), a monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow. Arzerra is approved for cancer patients who are no longer responding to the current available treatment options using fludarabine and alemtuzumab. Following the approval, Genmab has become eligible to receive a milestone payment of DKK 116 million (approximately $23 million) from Glaxo. Earlier, in May 2009, Arzerra had received a positive recommendation from the FDA&#8217;s Oncologic Drugs Advisory Committee (ODAC) in which the panel had voted 10-3 in favor of the drug. They had found that Arzerra provided some clinical benefit to patients with CLL whose disease was refractory to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/gsk-glaxosmithkline-earns-fda-approval-for-arzerra-a-chronic-lymphocytic-leukemia-drug/19135/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Reports Higher Earnings</title>
		<link>http://www.stockbloghub.com/2009/10/20/biib-biogen-reports-higher-earnings/18245</link>
		<comments>http://www.stockbloghub.com/2009/10/20/biib-biogen-reports-higher-earnings/18245#comments</comments>
		<pubDate>Tue, 20 Oct 2009 22:38:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18245</guid>
		<description><![CDATA[Today morning, Biogen Idec (BIIB) reported third quarter earnings per share of $1.12, beating the Zacks Consensus Estimate of $1.02. The company reported earnings of 98 cents in the year-ago period. Revenues increased 3% to $1.12 billion, with Tysabri being the primary growth driver. Tysabri sales came in at $207 million, up 21% from the prior period. The company estimates that as of the end of September 2009, about 46,200 patients were on commercial and clinical Tysabri therapy worldwide. This represents an increase from the 43,300 patients reported by the company in the second quarter of 2009. Tysabri is an important growth driver and we expect the product, which is partnered with Elan (ELN), to cross $1 billion in worldwide sales in 2009. Meanwhile, Biogen’s lead multiple sclerosis (MS) product ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/biib-biogen-reports-higher-earnings/18245/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Two Pharmas Are Better Than One &#8211; Here Are the Ones to Buy in This Merger-Mad Industry</title>
		<link>http://www.stockbloghub.com/2009/10/16/abt-two-pharmas-are-better-than-one-here-are-the-ones-to-buy-in-this-merger-mad-industry/17681</link>
		<comments>http://www.stockbloghub.com/2009/10/16/abt-two-pharmas-are-better-than-one-here-are-the-ones-to-buy-in-this-merger-mad-industry/17681#comments</comments>
		<pubDate>Fri, 16 Oct 2009 20:27:30 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Crucell N.v.]]></category>
		<category><![CDATA[CRXL]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17681</guid>
		<description><![CDATA[Tony Daltorio, Investment U Research Pharmaceutical companies have launched themselves into the fall season with a vengeance, gobbling up acquisitions like dots on a Pac-Man board. The most notable recent buyout was a deal that sees Abbott Laboratories (NYSE: ABT) expand both its product range and its presence in notable emerging nations with its purchase of Belgian-based Solvay Group’s pharmaceutical arm for a $6.5 billion fee. That price tag is just one indication of the money washing around this industry these days, which makes the current consolidation trend chock full of profitable opportunities. As Investment U’s own “takeover tracker” Louis Basenese does all the time, he positions investors for some pretty lucrative short-term profits by buying takeover targets, then riding those deals all the way into long-term profits by purchasing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/abt-two-pharmas-are-better-than-one-here-are-the-ones-to-buy-in-this-merger-mad-industry/17681/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson Beast Estimates and Raises Guidance</title>
		<link>http://www.stockbloghub.com/2009/10/14/jnj-johnson-johnson-beast-estimates-and-raises-guidance/17570</link>
		<comments>http://www.stockbloghub.com/2009/10/14/jnj-johnson-johnson-beast-estimates-and-raises-guidance/17570#comments</comments>
		<pubDate>Wed, 14 Oct 2009 16:37:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17570</guid>
		<description><![CDATA[Johnson &#38; Johnson’s (JNJ) third quarter earnings of $1.20 surpassed the Zacks Consensus Estimate by 7 cents and by 3 cents from the year-ago period. However, the company reported revenues of $15.1 billion, a decline of 5.3% compared to the third quarter of 2008. While 2.8% of the decline in revenue was due to operational factors, foreign exchange movement was responsible for the remaining 2.5% decline. Sales in both domestic and international markets recorded declines of 8.1% and 2.5%, respectively. Johnson &#38; Johnson’s diversified business model is helping the company pave its way through tough situations. For the second quarter in a row, the company’s medical devices segment posted higher revenues than the pharmaceuticals. While medical devices recorded an increase of 2.3% compared to the year-ago period, consumer products and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/14/jnj-johnson-johnson-beast-estimates-and-raises-guidance/17570/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ELN) SEC Subpoena for Elan Regarding Tysabri Use Disclosure</title>
		<link>http://www.stockbloghub.com/2009/10/14/eln-sec-subpoena-for-elan-regarding-tysabri-use-disclosure/17607</link>
		<comments>http://www.stockbloghub.com/2009/10/14/eln-sec-subpoena-for-elan-regarding-tysabri-use-disclosure/17607#comments</comments>
		<pubDate>Wed, 14 Oct 2009 15:31:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17607</guid>
		<description><![CDATA[Elan Corporation (ELN) recently received a subpoena from the US Securities and Exchange Commission (SEC) regarding the company’s disclosure of two brain disorder cases (in July 2008), often fatal, tied to the use of its drug Tysabri for the treatment of multiple sclerosis. Elan has a marketing agreement with Biogen Idec (BIIB) for Tysabri. In addition, the subpoena asked for detailed information regarding clinical trial data on bapineuzumab, a drug for the treatment of Alzheimer&#8217;s disease. Recently, Johnson &#38; Johnson (JNJ) paid $885 million for an 18.4% stake in Elan in addition to $500 million for a majority stake in the company’s Alzheimer&#8217;s disease pipeline. As a reminder, in July last year, both Elan and Biogen announced the occurrence of two cases of brain infection, progressive multifocal leukoencephalopathy [PML], in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/14/eln-sec-subpoena-for-elan-regarding-tysabri-use-disclosure/17607/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

